ClinicalTrials.gg
Sign In
CompletedNCT00244088Updated Sep 1, 2009

Study Evaluating the Etiology of Intra-Abdominal Infections

An observational study in Intra-abdominal Infection, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-09-01.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
340
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to define the etiology of intra-abdominal infections, to study the role of Enterococcus spp and Pseudomonas aeruginosa in these infections and to clarify the need for specific enterococcal antimicrobial coverage.

02

Conditions studied

  • Intra-abdominal Infection

Keywords

  • Abdominal infection
03

In context

Intraabdominal Infections

140 studies on the registry are indexed under Intraabdominal Infections; 16 are open to participants now.

This study's enrollment of 340 is above the median of 177 across 50 observational studies indexed under Intraabdominal Infections.

Browse Intraabdominal Infections studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Browse Wyeth studies →All Pfizer studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Surgery units

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A case will be defined as an intra-abdominal abscess or peritoneal fluid culture that will be positive for enterococcus or an enterococcal bacteriemia in association with an intra-abdominal source of infection.
  • A control will be defined as a culture-positive intra-abdominal infection or bacteriemia due to an intraabdominal focus where enterococci have not been isolated.

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
340 participants
Biospecimen retention
Samples without dna
06

Study locations

No study locations are listed for this record.

07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2005
First posted
Oct 25, 2005
Start
Apr 2004
Primary completionActual
Dec 2004
CompletionActual
Dec 2004
Last update
Sep 1, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00244088
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
First posted
Oct 25, 2005
Start date
Apr 2004
Primary completion
Dec 2004
Completion
Dec 2004
Last update
Sep 1, 2009

Study contacts

Medical Monitor
principal investigator · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Intraabdominal Infections →

Other studies from this sponsor

Wyeth is now a wholly owned subsidiary of Pfizer →

Start the discussion